OncRef

Clinical Trial: NCT06483282

A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer

Status:

RECRUITING

Phase:

Phase 2

Lead Sponsor:Jin Ying
Information Provided By:Zhejiang Cancer Hospital
Last Update Posted:2026-09-11

Study Overview

Brief Summary

This is a single-arm, prospective, exploratory phase II clinical study. The study enrolled newly diagnosed stage T1-3N0-1M0 resectable limited-stage small cell lung cancer. Adebrelimab combined with chemotherapy for 4 cycles and apatinib mesylate for 3 cycles. Surgery was performed within 4-8 weeks after the above treatment (the operation was performed 4 weeks after apatinib was discontinued). According to the results of MDT discussion, adebrelimab combined with apatinib mesylate combined with or without radiotherapy was started 4 weeks after surgery. Preoperative prophylactic radiotherapy (PCI) is recommended for patients with preoperative stage N1. Patients with postoperative stage N1 received postoperative thoracic radiotherapy.

Official Title

A Single-arm, Prospective, Exploratory Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer

Conditions

Small Cell Lung Cancer Limited Stage

Intervention / Treatment

  • Drug: Adebrelimab
  • Drug: Apatinib Mesylate
  • Drug: Etoposide
  • Drug: Carboplatin

Other Study ID Numbers

  • IRB-2024-420

Start Date (Actual)

2024-06-21

Primary Completion Date (Estimated)

2026-12-01

Study Completion Date (Estimated)

2026-12-31

Enrollment (Estimated)

38

Study Type

Interventional

Phase

Phase 2